Events

International Symposium on ALS/MND w/ Prof. Jackie Hunter

Join BenevolentAI’s Board Director, Jackie Hunter, for a talk on our AI-augmented search for disease-modifying treatments for ALS

The complex aetiology and heterogeneity of neurodegenerative diseases, such as ALS, has proved a formidable barrier to the translation of basic research into effective treatments. With a rapidly ageing global population, the need to address this unmet medical need becomes ever more pressing. The exponential increase in biomedical data generation and research output, however, offers confidence that we are on the cusp of making substantial progress. This presentation will examine how the application of this technology is helping to enhance the mechanistic understanding of human disease, therapeutic target identification and uncover more effective disease-modifying treatments for ALS and other neurodegenerative diseases.


Register here →


Jackie Hunter

Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI. Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds personal chairs from St George’s Hospital Medical School and Imperial College and serves on numerous Advisory Bodies and Boards including the Technology Advisory Board of BP plc and A*Star Board Singapore. She also Chairs the Boards of Brainomix Ltd, Stevenage Bioscience Catalyst and the Sainsbury Laboratories Norwich

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021